News

On March 2, 2018, the manufacturers of Zinbryta (daclizumab) – a drug used in the treatment of some forms of multiple sclerosis – announced that they would stop making the drug because of concerns about serious side effects.

PAI is excited to introduce a new Preferred Blue provider (PPO) network logo. This is a logo image change only and does not impact the provider network, network benefits, nor benefits verification.

As of July 1, 2018, we will no longer cover products that are classified as medical foods or food supplements.

The changes in this bulletin go into effect January 1, 2018, unless noted otherwise. They apply to PAI groups that use the Caremark Preferred Drug List.

The changes in this bulletin go into effect October 1, 2018, unless noted otherwise. They apply to PAI groups that use the Caremark Preferred Drug List.

PAI is dedicated to doing its part to reduce the over-prescribing of opioids to ultimately help reduce the number of new opioid addicts. The Pharmacy & Therapeutics (P&T) Committee has worked diligently to develop an Opioid Management Program slated to begin April 1, 2018.

At the National Workers’ Compensation and Disability Conference 2017 in Las Vegas, Nev., Bardavon Health Innovations and Planned Administrators, Inc. (PAI), a third party administrator for property and casualty, announced an integrated commercial health and workers’ compensation solution for large employers nationwide.

The changes in this bulletin go into effect January 1, 2018, unless noted otherwise. They apply to PAI groups that use the Caremark Preferred Drug List.

This notice is PAI’s standard procedure and is being shared for EMERGENCY Preparedness.

PAI is pleased to announce that Charlie Sears is taking on the new role of PAI Sales Executive. Through PAI’s acquisition of Companion TPA (CTPA), in the property and casualty space, PAI is excited to expand its offerings to now include a property and casualty offering and broaden Charlie’s role to include PAI’s full portfolio of administrative offerings.